白细胞介素-2和苦参碱对小鼠微小残留白血病的治疗作用

 目的 研究微小残留白血病的治疗新方法。方法 采用重组人白细胞介素-2（rhIL-2）和苦参碱单独或联合治疗小鼠多药耐药微小残留白血病。 DBA小鼠接种P388／VCR-G细胞（1×106／只）后第3天，用环磷酰胺（Cy）35 mg／kg一次腹腔注射，24 h 后实验分4组。对照组：腹腔注射生理盐水0.2 ml／次，2次／d，连续5 d。rhIL-2组：腹腔注射rhIL-2 1×105U／次，2次／d，连续5 d。苦参碱组：腹腔注射苦参碱25 mg／kg，1次／d，连续5 d。rhIL-2＋苦参碱组：腹腔注射rhIL-2 1×105U／次，2次／d，连续5 d；苦参碱25 mg／kg，1次／d，连续5 d。结果 对照组小鼠平均生存期（25.2±1.10）d，rhIL-2治疗组平均生存期分别延长至（36.25±1.26）d，按回归方程y天数= -1.98x细胞数+28.61推算，相当于杀灭了1×103左右的白血病细胞。苦参碱治疗组平均生存期分别延长至（37.8±13.7）d，亦相当于杀灭了1×103左右的白血病细胞。rhIL-2联合苦参碱治疗组平均生存期为（37.0±1.87）d，与单用比较无统计学差异（P＞0.05）。结论 rhIL-2和苦参碱单独应用均有显著抑制微小残留白血病细胞增生的作用，但两者联合应用无明显协同作用

Effect on minimal residual leukemia in mice model by interlukin-2 and matrine

Objective To investigate therapy on minimal residual leukemia (MRL) in animal model. Methods Recombinant human interlukin-2 (rhIL-2) and matrine were adopted treating mice with MRL. After 3 days DBA mice inoculated by P388/VCR-G cells (1×106/one mouse), were treated by 35 mg/kg cyclophosphamide (Cy). After 24 hours, all of the mice individed 4 groups, normal saline was injected was injected continously 5 days in control group，rhIL-2 was injected continuously 5 days in rhIL-2 group, matrine was injected continously 5 days in matrine group, rhIL-2 and matrine were injected for 5 days in rhIL-2 and matrine group. Results The mean survival time of the DBA mice was 25.2±1.1 days in control group, and that in rhIL-2 group was 36.25±1.26 days. According to the regression equation yday＝-1.98X number of cells＋28.61, it equaled to eradicate about 103 leukemia cells. The survival time of matrine group was 37.8±13.7 days, and it e-qualed to eradicate at least 103 leukemia cells, too. The survival time of rhIL-2 and matrine combined modality was 37.0±1.87 days, it had no significant statistical different compared with survival time of rhIL-2 or matrine group. Conclusion rhIL-2 or matrine could inhibit prolifera-tive of residual leukemic cells in complete remission stage, but there was not synergetic effect between rhIL-2 and matrine.